Emerging mechanism‑driven therapies for endometriosis: From GnRH antagonists to microbiome and device‑based strategies (Review)
Year: 2026
Type: review
Abstract: Millions of women of reproductive age suffer from endometriosis, a chronic, estrogen-driven condition that causes pelvic pain, dysmenorrhea and infertility.Conventional therapy focuses on symptom suppression with hormone medications or the surgical excision of lesions; however, it is not curative.Recent developments in the understanding of the pathophysiology of endometriosis have revealed novel immunological and molecular mechanisms that are being used in experimental therapies.The present review outlines developing techniques, including targeted endocrine modulators, epigenetic treatments, anti-inflammatory and immunomodulatory drugs, antioxidants, anti-angiogenic medicines, and microbiome-based therapy.Prominent examples are new oral gonadotropin-releasing hormone receptor antagonists, selective progesterone receptor modulators and aromatase inhibitors that aim to overcome progesterone resistance.Alternative methods, such nutraceuticals and biologic and small-molecule inhibitors (such as metabolic drugs and anti-cytokine therapies) are being explored.Novel supplemental options are provided by device-based neuromodulation and improved surgical techniques (such as advanced laparoscopy, robotic excision, image-guided surgery, nerve-sparing techniques and adhesion barriers).While many of these innovations are promising, current evidence is limited by small studies and disease heterogeneity.Future directions emphasize rigorous trials with standardized outcomes, including fertility measures and combinations of therapies to achieve personalized, long-term relief.Contents 1. Introduction 2. Pathophysiological targets driving emerging endometriosis therapies 3. Current standard of care 4. Emerging medical therapies 5. Surgical/device innovations and procedural adjuncts 6. Biomarkers, diagnostics and precision medicine 7. Clinical trial landscape, regulatory status and approval pathways 8. Safety, tolerability, fertility and contraceptive considerations 9. Cost, accessibility and health system considerations 10.Evidence gaps, limitations and quality of existing evidence 11.Future directions 12.
Source: Medicine International
DOI: 10.3892/mi.2026.341
Institutions: Tbilisi State Medical University, University of Georgia
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7214621016